A carregar...
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
BACKGROUND: We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. METHODS: Patients from the nilotinib registration trial (CAMN107A2101; registered at http://www.cli...
Na minha lista:
Main Authors: | , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2013
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3646679/ https://ncbi.nlm.nih.gov/pubmed/23547655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-173 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
https://ncbi.nlm.nih.gov/pmc/articles/PMC3646679/https://ncbi.nlm.nih.gov/pubmed/23547655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-173
Cannot write session to /tmp/vufind_sessions/sess_91c1u3feld8d8kg35ivteuvul4